244 related articles for article (PubMed ID: 31242489)
1. Efficacy and Safety of Cetuximab plus Radiotherapy in Cisplatin-Unfit Elderly Patients with Advanced Squamous Cell Head and Neck Carcinoma: A Retrospective Study.
Addeo R; Caraglia M; Vincenzi B; Luce A; Montella L; Mastella A; Mazzone S; Ricciardiello F; Carraturo M; Del Prete S; Sperlongano P
Chemotherapy; 2019; 64(1):48-56. PubMed ID: 31242489
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of concurrent carboplatin plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin.
Hamauchi S; Yokota T; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H
Jpn J Clin Oncol; 2015 Dec; 45(12):1116-21. PubMed ID: 26423341
[TBL] [Abstract][Full Text] [Related]
3. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of concurrent carboplatin or cetuximab plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin.
Hamauchi S; Yokota T; Mizumachi T; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H; Homma A
Int J Clin Oncol; 2019 May; 24(5):468-475. PubMed ID: 30656463
[TBL] [Abstract][Full Text] [Related]
5. Radical radiotherapy with concurrent weekly cisplatin in loco-regionally advanced squamous cell carcinoma of the head and neck: a single-institution experience.
Gupta T; Agarwal JP; Ghosh-Laskar S; Parikh PM; D'Cruz AK; Dinshaw KA
Head Neck Oncol; 2009 Jun; 1():17. PubMed ID: 19527507
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study.
Merlano M; Russi E; Benasso M; Corvò R; Colantonio I; Vigna-Taglianti R; Vigo V; Bacigalupo A; Numico G; Crosetto N; Gasco M; Lo Nigro C; Vitiello R; Violante S; Garrone O
Ann Oncol; 2011 Mar; 22(3):712-717. PubMed ID: 20810547
[TBL] [Abstract][Full Text] [Related]
7. Toxicity and outcomes in combined modality treatment of head and neck squamous cell carcinoma: cisplatin versus cetuximab.
Ye AY; Hay JH; Laskin JJ; Wu JS; Ho CC
J Cancer Res Ther; 2013; 9(4):607-12. PubMed ID: 24518704
[TBL] [Abstract][Full Text] [Related]
8. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
Bonner JA; Harari PM; Giralt J; Azarnia N; Shin DM; Cohen RB; Jones CU; Sur R; Raben D; Jassem J; Ove R; Kies MS; Baselga J; Youssoufian H; Amellal N; Rowinsky EK; Ang KK
N Engl J Med; 2006 Feb; 354(6):567-78. PubMed ID: 16467544
[TBL] [Abstract][Full Text] [Related]
9. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm.
Pfister DG; Su YB; Kraus DH; Wolden SL; Lis E; Aliff TB; Zahalsky AJ; Lake S; Needle MN; Shaha AR; Shah JP; Zelefsky MJ
J Clin Oncol; 2006 Mar; 24(7):1072-8. PubMed ID: 16505426
[TBL] [Abstract][Full Text] [Related]
10. Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma.
Fayette J; Molin Y; Lavergne E; Montbarbon X; Racadot S; Poupart M; Ramade A; Zrounba P; Ceruse P; Pommier P
Drug Des Devel Ther; 2015; 9():6203-10. PubMed ID: 26648696
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
Bonner JA; Harari PM; Giralt J; Cohen RB; Jones CU; Sur RK; Raben D; Baselga J; Spencer SA; Zhu J; Youssoufian H; Rowinsky EK; Ang KK
Lancet Oncol; 2010 Jan; 11(1):21-8. PubMed ID: 19897418
[TBL] [Abstract][Full Text] [Related]
12. Conventional radiotherapy with concurrent weekly Cisplatin in locally advanced head and neck cancers of squamous cell origin - a single institution experience.
Dimri K; Pandey AK; Trehan R; Rai B; Kumar A
Asian Pac J Cancer Prev; 2013; 14(11):6883-8. PubMed ID: 24377620
[TBL] [Abstract][Full Text] [Related]
13. Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The RTOG Experience.
Bar-Ad V; Zhang QE; Harari PM; Axelrod R; Rosenthal DI; Trotti A; Jones CU; Garden AS; Song G; Foote RL; Raben D; Shenouda G; Spencer SA; Harris J; Le QT
Int J Radiat Oncol Biol Phys; 2016 Aug; 95(5):1346-1354. PubMed ID: 27212198
[TBL] [Abstract][Full Text] [Related]
14. IMRT with simultaneous integrated boost and concurrent chemotherapy for locoregionally advanced squamous cell carcinoma of the head and neck.
Montejo ME; Shrieve DC; Bentz BG; Hunt JP; Buchman LO; Agarwal N; Hitchcock YJ
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e845-52. PubMed ID: 21167654
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma.
Fury MG; Xiao H; Sherman EJ; Baxi S; Smith-Marrone S; Schupak K; Gewanter R; Gelblum D; Haque S; Schoder H; Shah JP; Katabi N; Kurtzman R; Lipson B; Cox L; Lee NY; Pfister DG
Head Neck; 2016 Apr; 38 Suppl 1(Suppl 1):E566-70. PubMed ID: 25784616
[TBL] [Abstract][Full Text] [Related]
16. Cetuximab with radiotherapy in patients with loco-regionally advanced squamous cell carcinoma of head and neck unsuitable or ineligible for concurrent platinum-based chemo-radiotherapy: Ready for routine clinical practice?
Agarwal JP; Gupta T; Kalyani N; Budrukkar A; Laskar SG; Murthy V; Kumar P; Narohna V; Pai P; Chaturvedi P; D'cruz AK
Indian J Cancer; 2011; 48(2):148-53. PubMed ID: 21768657
[TBL] [Abstract][Full Text] [Related]
17. Individualized treatment of head neck squamous cell carcinoma patients aged 70 or older with radiotherapy alone or associated to cisplatin or cetuximab: impact of weekly radiation dose on loco-regional control.
Belgioia L; Bacigalupo A; Missale F; Vecchio S; Chiola I; Callegari S; Verzanini E; Peretti G; Corvò R
Med Oncol; 2019 Mar; 36(5):42. PubMed ID: 30927146
[TBL] [Abstract][Full Text] [Related]
18. [Concurrent simultaneous integrated boost radiotherapy and cetuximab in head and neck squamous cell cancer patients: is it feasible in daily clinical practice?].
Chillari F; Parisi S; Ferrantelli G; Carrubba C; Santacaterina A; Critelli P; Sciacca M; Venuti V; Lillo S; Cacciola A; Iatì G; Pontoriero A; Platania A; Delia P; Tombolini V; De Felice F; Musio D; Spatola C; Brogna A; Pergolizzi S
Recenti Prog Med; 2024 May; 115(5):1e-6e. PubMed ID: 38708539
[TBL] [Abstract][Full Text] [Related]
19. Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial.
Elbers JBW; Al-Mamgani A; Tesseslaar MET; van den Brekel MWM; Lange CAH; van der Wal JE; Verheij M; Zuur CL; de Boer JP
Radiother Oncol; 2020 Jan; 142():79-84. PubMed ID: 31563412
[TBL] [Abstract][Full Text] [Related]
20. Assessing Care Value for Older Patients Receiving Radiotherapy With or Without Cisplatin or Cetuximab for Locoregionally Advanced Head and Neck Cancer.
Saraswathula A; Chen MM; Colevas AD; Divi V
JAMA Otolaryngol Head Neck Surg; 2019 Dec; 145(12):1160-1167. PubMed ID: 31621810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
